Loading patent…
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsMelissa M. Herbst-Kralovetz, Pawel Laniewski
Estimating the term…
Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and/or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and/or predicting women who are “at risk” for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a cervicovaginal lavage (CVL) or vaginal swab sample from a patient and producing a profile of at least five or more biomarkers from the collected sample.
A method of monitoring a treatment for endometrial cancer (EC) in a subject in need thereof, the method comprising;
A method of monitoring a treatment for endometrial cancer (EC) in a subject in need thereof, the method comprising;
A method comprising:
The method of embodiment 17, wherein producing a profile comprises detecting at least ten or more biomarkers.
The method of embodiment 17, wherein the method predicts the risk of endometrial hyperplasia or cancer in women.
The method of embodiment 17, wherein the method diagnoses endometrial cancer in women.
Dependencies are inferred from the claim text.